New Enterprise Associates related stories
All articles and analysis
Verona Pharma debuts IPOLondon-based Verona Pharma, a biopharmaceutical company, has priced its IPO of over 5.8 million shares at $13.50 per share. The stock began trading April 27, 2017 on the NASDAQ under the ticker symbol “VRNA.” Jefferies and Stifel are serving as the lead underwriters. Verona Pharma’s backers include Vivo Capital, OrbiMed, New Enterprise Associates, Abingworth, Henderson Global Investors and Aisling Capital.
- NEA leads $12 mln round for ChromaCode
Carlsbad, California-based ChromaCode Inc, a molecular diagnostics company, has secured $12 million in Series B funding. New Enterprise Associates led the round with participation from return backers Domain Associates and Okapi Ventures.
- Trading startup Robinhood raises $110 million in new funding round: Reuters
Commission-free trading startup Robinhood has raised $110 million in a round led by Russian billionaire Yuri Milner's investment group DST Global, valuing the company at $1.3 billion, Reuters reported.
- GGV Capital leads funding round in Gladly
San Francisco-based Gladly, which provides customer service-oriented software, announced it has raised $36 million in Series C funding. GGV Capital led the round, which included existing investors Greylock Partners and New Enterprise Associates. The company has now raised $63 million in total funding.
- VC-backed EverFi acquires Workplace Answers
EverFi has acquired Austin, Texas-based Workplace Answers, an online compliance training company. No financial terms were disclosed. EverFi's backers included Bezos Expeditions, New Enterprise Associates, Tomorrow Ventures and Rethink Education.
- Reltio nabs $40 mln Series C
Redwood Shores, California-based Reltio, an enterprise data-driven applications and modern data management platform as a service company, has secured $40 million in Series C funding. New Enterprise Associates led the round with participation from Sapphire Ventures, Crosslink Capital and.406 Ventures.
